Mouse Granulocyte-Macrophage Colony-Stimulating Factor, Csf2 Primacu™ ELISA Kit

Mouse Granulocyte-Macrophage Colony-Stimulating Factor, Csf2 Primacu™ ELISA Kit

• Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility. Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy
• Description: Granulocyte-macrophage colony-stimulating factor
• Synonyms: Csfgm
• Gene Name: Csf2
• Gene ID: 12981
• UniProt: P01587
• Origin Species: Mouse
• Reactivity: Mouse
• Target: GM-CSF
• Field of Research: Immunology,Neuroscience
• Assay Type: Sandwich
• Assay Performance Time: 3.5 Hours
• Standard: 1.2 ng/mL
• Sample Type: Serum, plasma, cell culture supernates
• Detection Range: 1.88-120 pg/mL
• Sensitivity: 0.59 pg/mL
• Weight: 16091
• Storage Temperature: 2-8°C